Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

Shaji K Kumar, Hajime Uno, Susanna J. Jacobus, Scott A. Van Wier, Greg J. Ahmann, Kimberly J. Henderson, Natalie S. Callander, Jessica L. Haug, David S. Siegel, Philip R. Greipp, Rafael Fonseca, S Vincent Rajkumar

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio ∇ 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.

Original languageEnglish (US)
Pages (from-to)4359-4362
Number of pages4
JournalBlood
Volume118
Issue number16
DOIs
StatePublished - Oct 20 2011

Fingerprint

Gene Expression Profiling
Gene expression
Dexamethasone
Therapeutics
lenalidomide
Metaphase
Multiple Myeloma
Cytogenetics
Chromosome Aberrations
Hazards
Statistics
Survival

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. / Kumar, Shaji K; Uno, Hajime; Jacobus, Susanna J.; Van Wier, Scott A.; Ahmann, Greg J.; Henderson, Kimberly J.; Callander, Natalie S.; Haug, Jessica L.; Siegel, David S.; Greipp, Philip R.; Fonseca, Rafael; Rajkumar, S Vincent.

In: Blood, Vol. 118, No. 16, 20.10.2011, p. 4359-4362.

Research output: Contribution to journalArticle

Kumar, SK, Uno, H, Jacobus, SJ, Van Wier, SA, Ahmann, GJ, Henderson, KJ, Callander, NS, Haug, JL, Siegel, DS, Greipp, PR, Fonseca, R & Rajkumar, SV 2011, 'Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone', Blood, vol. 118, no. 16, pp. 4359-4362. https://doi.org/10.1182/blood-2011-03-342089
Kumar, Shaji K ; Uno, Hajime ; Jacobus, Susanna J. ; Van Wier, Scott A. ; Ahmann, Greg J. ; Henderson, Kimberly J. ; Callander, Natalie S. ; Haug, Jessica L. ; Siegel, David S. ; Greipp, Philip R. ; Fonseca, Rafael ; Rajkumar, S Vincent. / Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. In: Blood. 2011 ; Vol. 118, No. 16. pp. 4359-4362.
@article{2c26a0a415714d4aa1dcf49c6c1807fe,
title = "Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone",
abstract = "Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16{\%}) and 10 (22{\%}), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio ∇ 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.",
author = "Kumar, {Shaji K} and Hajime Uno and Jacobus, {Susanna J.} and {Van Wier}, {Scott A.} and Ahmann, {Greg J.} and Henderson, {Kimberly J.} and Callander, {Natalie S.} and Haug, {Jessica L.} and Siegel, {David S.} and Greipp, {Philip R.} and Rafael Fonseca and Rajkumar, {S Vincent}",
year = "2011",
month = "10",
day = "20",
doi = "10.1182/blood-2011-03-342089",
language = "English (US)",
volume = "118",
pages = "4359--4362",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

AU - Kumar, Shaji K

AU - Uno, Hajime

AU - Jacobus, Susanna J.

AU - Van Wier, Scott A.

AU - Ahmann, Greg J.

AU - Henderson, Kimberly J.

AU - Callander, Natalie S.

AU - Haug, Jessica L.

AU - Siegel, David S.

AU - Greipp, Philip R.

AU - Fonseca, Rafael

AU - Rajkumar, S Vincent

PY - 2011/10/20

Y1 - 2011/10/20

N2 - Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio ∇ 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.

AB - Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio ∇ 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.

UR - http://www.scopus.com/inward/record.url?scp=80054840882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054840882&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-03-342089

DO - 10.1182/blood-2011-03-342089

M3 - Article

C2 - 21860025

AN - SCOPUS:80054840882

VL - 118

SP - 4359

EP - 4362

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -